Safe travel, cold plunges and hot flashes: The week in Well+Being
You are reading our weekly Well+Being newsletter. Sign up here to get it delivered to your inbox every Thursday.
If your summer travel plans start with a trip to the airport, you might be a bit concerned about one infectious disease that's making a comeback: measles. Although it was officially eliminated 25 years ago, the United States is now experiencing a pretty big outbreak. The Centers for Disease Control and Prevention told The Washington Post this week that there have been 62 known cases of people with measles who traveled on commercial airlines, and at least one person who caught the infection presumably from someone seated nearby.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Grandfather's simple changes reversed pre-diabetes diagnosis that left him 'petrified'
A 66-year-old grandfather who exercised daily was stunned to learn he was pre-diabetic — and he says making one small change to his eating habits helped reverse it. Dance teacher Will McKechnie, from Lytham St Annes, Lancashire, told SWNS he had always considered himself healthy. At 5 feet 10 inches tall and 167 pounds, he wore a medium-sized shirt, danced seven times a week, and didn't think twice about his daily snacks: a chocolate bar and a bag of chips. Experts Reveal Hidden Ways Sugar Accelerates Aging Beyond Just Weight Gain "I honestly thought I was really fit and healthy," McKechnie said. But after undergoing a free screening for people over 60 in May 2023, a routine blood test showed that his average blood sugar level was 6.2% — an indicator of pre-diabetes, according to SWNS. Read On The Fox News App McKechnie didn't find out until a year later, during an unrelated appointment, when his doctor reviewed the results. "I was so shocked and worried to hear I was pre-diabetic," he said. 'I'm A Neurologist — Here's Why Dementia Is Rising And How To Reduce Your Risk' McKechnie continued, "When he said it wouldn't be reversible over 48, I was terrified. I was petrified at the idea that I might be starting to have poor health." Determined to turn things around, McKechnie made some major changes — not only in what he ate, but how. He cut out the nightly chocolate and chips, started eating whole, nutritious foods, and began chewing his food much more slowly. Now, his lunch — a wholemeal chicken sandwich — takes him 40 minutes to eat. "I just have a very occasional treat now, and much smaller," McKechnie told SWNS. Golfer Phil Mickelson's Strict Weight Loss Diet: Doctor Shares What To Know His breakfast now consists of fruit, and a typical dinner includes boiled eggs, roasted peanuts, celery, cherry tomatoes, carrots and cucumber. By focusing on slower eating and more mindful food choices, McKechnie shed nearly 27 pounds, bringing him down to 142 pounds and a size small shirt. He also lost two inches off his waist — and, more importantly, his blood sugar dropped to 5.9% within nine months, SWNS reported. "I'm very determined," McKechnie said. He added, "If I set my mind to doing something, I'll do it, and I'm going to get my blood sugar even lower." The grandfather of four said he no longer battles sugar cravings and doesn't feel the urge to rush into stores for a chocolate fix. He also stays busy caring for his 18-month-old grandson and teaching two dance classes a week. McKechnie, who quit smoking in 1986 and stopped drinking in 2012, believes everyone should be proactive about checking their health — even if they look healthy on the outside. Click Here To Sign Up For Our Health Newsletter "Even if you have to pay for it, it's worth getting your blood sugar checked routinely," he told SWNS, adding, "It's much, much better to find out." For more Health articles, visit According to SWNS, McKechnie now says he feels stronger than ever and has "enormous amounts of energy." "I'm so relieved I had that test. It has changed my life and made me so much fitter."Original article source: Grandfather's simple changes reversed pre-diabetes diagnosis that left him 'petrified'
Yahoo
27 minutes ago
- Yahoo
ThinkCareBelieve: Week 22 of America's Rise to Greatness under President Trump's Leadership
Washington, DC, June 21, 2025 (GLOBE NEWSWIRE) -- Link to ThinkCareBelieve's Article: has published an article about Week 22 of America's rise to greatness. This week entailed outstanding leadership by a steady hand through choppy waters and ThinkCareBelieve's article shows how the President kept moving forward at a strong, surefooted pace. ThinkCareBelieve's article has important progress made at the G7 and the signing of major trade agreements as tensions between Iran and Israel took place. The message from Press Secretary Karoline Leavitt this week was "Trust in President Trump." Great nations are made because of great leaders and this week was proof of it. America has just had the highest wage increase in 60 years and the article has it. Real blue collar wages are up nearly 2%! America's low inflation and rising wages is a sure sign of success. Two new 88 foot high flag poles were installed this week, a magnificent addition to the White House grounds. The article has the latest on the status of student visas from Secretary of State Marco Rubio and President Trump's approval numbers keep going up! The article covers the Genius Act being passed by the Senate and the announcement that 70,000 people have signed up for President Trump's Gold Card Visa. The article has an abundance of reasons the One Big Beautiful Bill will benefit Americans. The OBBB will drive growth and supercharge the American economy. The article even has a tax-free tips and overtime calculator to see the average savings in your state: The article has statements by Dr. OZ the Administrator of the Center for Medicaid and Medicare Services on just how the One Big Beatiful Bill will help the most vulnerable of us who will suffer if the OBBB is not passed. The article also covers the great strides made by Secretary Kennedy convincing major food manufacturers to remove artificial food dyes and chemicals from their foods. The article also has an announcement by U.S. Attoney Jeanine Pirro of the U.S. Department of Justice crackdown on Crypto Currency Confidence Scams with confiscation and seizure of stolen money being returned back to the victims. Numerous investigations commenced this week and ThinkCareBelieve's article has the surge in attacks on ICE as they tried to do their jobs arresting criminal illegal aliens, catching child predators and dismantling trafficking networks. President Trump is the Man in the Arena and we are witessing history seeing how this man leads us through the muck and the mire to peace and prosperity in America's Golden Age. is an outlook. ThinkCareBelieve's mission for Peace advocacy facilitates positive outcomes and expanded possibilities. To achieve Peace, we will find the commonalities between diverse groups and bring the focus on common needs, working together toward shared goals. Activism is an important aspect of ThinkCareBelieve, because public participation and awareness to issues needing exposure to light leads to justice. Improved transparency in government can lead to changes in policy and procedure resulting in more fluid communication between the public and the government that serves them. America needs hope right now, and Americans need to be more involved in their government. ### CONTACT: CONTACT: Joanne COMPANY: ThinkCareBelieve EMAIL: joanne@ WEB: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
